Eupraxia Pharmaceuticals (EPRX) Consolidated Net Income (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Consolidated Net Income data on file, last reported at -$12.6 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 86.87% year-over-year to -$12.6 million in Q1 2026; TTM through Mar 2026 was -$27.8 million, a 117.57% decrease from a year earlier, with the FY2025 full-year figure at -$38.6 million, down 49.96% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$12.6 million, down from -$6.4 million in the prior quarter.
• Over the last five years, Consolidated Net Income for EPRX reached as high as -$4.0 million in Q1 2023 and fell as low as -$12.6 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$7.2 million across 4 years, with a median of -$6.4 million in 2025.
• Across the five-year window, Consolidated Net Income slipped 6.32% in 2025 and slumped 86.87% in 2026, its largest moves.
• Year by year, Consolidated Net Income stood at -$4.0 million in 2023, then sank by 51.45% to -$6.0 million in 2024, then dropped by 6.32% to -$6.4 million in 2025, then slumped by 98.45% to -$12.6 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$12.6 million in Q1 2026, -$6.4 million in Q3 2025, and -$8.7 million in Q2 2025.